Lilly backs doc-payment disclosure law

Let the sun shine in. A federal proposal requiring drug and device makers to disclose payments to doctors got a boost yesterday when Eli Lilly became the first Big Pharma to back it. Why fess up on gifts, honoraria, travel, and cash payments to physicians? "We believe that being transparent is one way to help re-establish" public confidence in the relationship between doctors and drug makers, according to Dr. Jack Harris, a Lilly VP.

That may be. But the real turning point may have come when lawmakers agreed to raise the threshold for disclosure to $500 from $25--quite a leap--and to apply the rules to all drug and device makers, rather than just companies with more than $100 million in annual sales. Fines were cut, also; now they'd be between $1,000 and $50,000 per violation rather than between $10,000 to $100,000. Plus, the legislation would preempt any state rules on disclosure.

- check out Lilly's statement on the move
- read the Associated Press story
- see the Indianapolis Star's coverage
- get the item from Pharmalot

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.